MAPT and Alzheimer disease: This subtype is also associated with elevated tau and phosphorylated tau (ptau) and reduced amyloid-beta (Aβ) levels in the CSF, indicating a more severe AD stage for these individuals (t-test p<0.001 Bonferroni corrected for multiple comparisons).